Hepatitis-B immunoglobulin in prevention of HBs antigenaemia in haemodialysis patients.
In a double-blind study, hepatitis-B immunoglobulin significantly protected patients in a haemodialysis unit against the development of HBs antigenaemia, compared to control patients receiving normal human immunoglobulin (p less than 0-01). Injections were given at the beginning and after 6 months, and observations extended over 16 months. Analysis of antiHBc and anti-HBs antibodies suggested that neutralisation of the virus inoculum, as well as modification of infection, may be implicated in the prevention of HBs antigenaemia.
D000328:Adult; D000906:Antibodies / Q000008:administration & dosage*; D000914:Antibodies, Viral / Q000302:isolation & purification; D002986:Clinical Trials as Topic; D006509:Hepatitis B / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000008:administration & dosage*; D006511:Hepatitis B Antigens / Q000302:isolation & purification; D006515:Hepatitis B virus / Q000276:immunology; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage*; D006435:Renal Dialysis; D013997:Time Factors
D000906:Antibodies; D000914:Antibodies, Viral; D006510:Hepatitis B Antibodies; D006511:Hepatitis B Antigens; D007136:Immunoglobulins